Related Experiment Video
Updated: Jun 20, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Clofarabine: emerging role in leukemias
Keeran Sampat1, Hagop Kantarjian, Gautam Borthakur
1University of Texas, MD Anderson Cancer Center, Leukemia Department, 1515 Holcombe Boulevard, Box 0428, Houston, TX 77030, USA.
Expert Opinion on Investigational Drugs
|September 1, 2009
Summary
Clofarabine, a purine nucleoside analogue, shows efficacy in treating pediatric leukemias and adult myeloid leukemias by inhibiting DNA synthesis. Its potential in older acute myeloid leukemia patients and an oral formulation are under development.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Clofarabine is a purine nucleoside analogue with established antineoplastic activity.
- Its mechanism involves inhibiting ribonucleotide reductase and DNA incorporation.
- Clofarabine has demonstrated efficacy in specific pediatric leukemias.
Purpose of the Study:
- To review the efficacy of clofarabine in various hematologic malignancies.
- To highlight its potential in adult myeloid leukemias and myelodysplastic syndromes.
- To discuss its promise for older acute myeloid leukemia patients and ongoing formulation development.
Main Methods:
- Review of existing clinical data and preclinical studies on clofarabine.
- Analysis of efficacy and safety profiles in pediatric and adult patient populations.
- Examination of the drug's mechanism of action and pharmacokinetic properties.
Main Results:
- Clofarabine exhibits significant efficacy in selected pediatric leukemias.
- It is effective alone and in combination for adult myeloid leukemias and high-risk myelodysplastic syndromes.
- Promising results are observed in older acute myeloid leukemia patients unsuitable for standard chemotherapy.
Conclusions:
- Clofarabine is a valuable therapeutic agent for specific leukemias and myelodysplastic syndromes.
- Further research supports its use in challenging patient populations.
- Development of an oral formulation may expand treatment accessibility.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...